2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sarah Temin,Timothy Aliff,Sherman Baker,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,William Pao,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TLDR
This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.Abstract:
Purpose An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy. Clinical Context Recent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable. Recent Data Seven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who receiv...read more
Citations
More filters
Journal ArticleDOI
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Jean-Louis Pujol,Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Paolo Bidoli,Jesus Corral,Belen San Antonio,Nadia Chouaki,William J. John,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +12 more
TL;DR: Overall, the incidence of low-grade fatigue, anemia, and neutropenia decreased with long-term pemetrexed exposure; however, renal events increased across treatment arms and EQ-5D analyses demonstrated no treatment-by-time interaction or overall treatment differences between the 2 arms.
Journal ArticleDOI
Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma
Ling Li,Ji-Ye Yin,Fa-Zhong He,Ma-Sha Huang,Tao Zhu,Yuan-Feng Gao,Yi-Xin Chen,Dong-Bo Zhou,Xiang Chen,Lun-Quan Sun,Wei Zhang,Hong-Hao Zhou,Zhao-Qian Liu +12 more
TL;DR: It is demonstrated that SFTA1P might serve as a useful biomarker for LSCC diagnosis and a predictor for cisplatin chemotherapy response in patients with LSCC and up-regulate hnRNP-U expression.
Journal ArticleDOI
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer ☆
Masato Karayama,Naoki Inui,Tomoyuki Fujisawa,Noriyuki Enomoto,Yutaro Nakamura,Shigeki Kuroishi,Koshi Yokomura,Naoki Koshimizu,Masaki Sato,Mikio Toyoshima,Toshihiro Shirai,Masafumi Masuda,Takashi Yamada,Shiro Imokawa,Takafumi Suda +14 more
TL;DR: Both maintenance therapy with pemetrexed alone and pemet Rexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetRexed, and beVacizuab.
Journal ArticleDOI
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
A. Davidson,Anne-Sophie Veillard,A. Tognela,M.M.K. Chan,B.G.M. Hughes,M. Boyer,K. Briscoe,S. Begbie,E. Abdi,C. Crombie,J. Long,A. Boyce,C.R. Lewis,S. Varma,A. Broad,N. Muljadi,S. Chinchen,David Espinoza,X. Coskinas,N. Pavlakis,Michael Millward,M.R. Stockler,Brett G.M. Hughes,Michael Boyer,Karen Briscoe,Andrew Davidson,Stephen Begbie,E Abdi,Catherine Crombie,Jeremy Long,Kevin Jasas,Craig R. Lewis,Adam Boyce,Suresh Vama,Adam Broad,Vy. Broaddge,David Gibbs,Robert Blum,Sue-Anne McLachlan,Andrew Haydon,Victoria J Bray,Janette L. Vardy,Girish Mallesara,Ray M. Lowenthal,Ray Asghari,Susan Tiley,Theresa Hayes,Mohammed Islam,Steven Ackland,Jacqui Adams,Nick Pavlakis,Martin R. Stockler,Nick Muljadi,Xanthi Coskinas,Sarah Chinchen,Matthew T. V. Chan,Annette Tognela,Danielle Ferraro,Rasha Cosman +58 more
TL;DR: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further.
Journal ArticleDOI
Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
Niels Reinmuth,A. Meyer,D. Hartwigsen,C. Schaeper,G. Huebner,R. Skock-Lober,A. Bier,U. Gerecke,C.-P. Held,M. Reck +9 more
TL;DR: Overall, oral vinorelbine plus cisplatin showed a high level of efficacy and adequate tolerability in first line treatment of NSCLC and seems to confirm the previous results reported in Asian patients.
References
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
J Oan H. S Chiller,D Avid H Arrington,C Handra P. B Elani,C Orey L Anger,A Lan S Andler,J Ames K Rook,J Unming Z Hu,D Avid H. J Ohnson +7 more
TL;DR: The response rate for all 1155 eligible pa-tients was 19 percent, with a median survival of 79 months (95 percent confidence interval, 73 to 85), a1-year survival rate of 33 percent, and a 2-year surviv-al rate of 11 percent.
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw,John Crowley,Kari Chansky,Dorothy J. Giroux,Patti A. Groome,Ramón Rami-Porta,Pieter E. Postmus,Valerie W. Rusch,Leslie H. Sobin +8 more
TL;DR: Suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Related Papers (5)
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more